Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on ...

Mucosal surfaces serve as critical battlegrounds where the immune system must balance tolerance to commensal organisms with rapid defense against pathogens.

New research identifies a specific monocyte gene signature that predicts mortality in IPF, offering potential targets ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

For years, orange juice has been sold as a simple source of vitamin C, but new human data suggest that a morning glass may be ...

The ImmunoSep trial set out to test whether an individualized approach—based on identifying either macrophage activation–like ...

Study links anxiety to 74% fewer natural killer cells—immune defenders against cancer and infections. Insomnia intensifies ...

A male in his 50s presented to the renal department with a diagnostic challenge of an unexplained kidney injury.

Platelet-to-Lymphocyte Ratio (PLR): Elevated PLR is another key marker linked to more aggressive tumor characteristics, such ...

Best of all, you won’t lose any of your hard-won gains: studies show it takes four to six weeks of pure inactivity – we’re ...